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Abstract 
The increasing cost of health care combined with expensive new drugs and diagnostics is 
leading to more frequent gaps between regulatory and reimbursement approval decisions. As a 
result, persons with Alzheimer’s disease may have difficulty accessing the benefits of medical 
advances. In contrast to the long history and established structure for drug approval, payer 
decision-making is dispersed, not standardized and perspectives on necessary evidence differ and 
often poorly defined. Particularly challenging is how to demonstrate the value of drugs and 
diagnostics for patients who do not yet have significant functional decline. While discussions to 
develop consensus continue, clinical trials should begin to incorporate health system and patient-
oriented outcomes. In some situations additional studies designed to demonstrate value and 
comparative effectiveness will be needed. Such studies should examine outcomes of 
representative populations in community settings. To assure scientific advances in diagnosis and 
treatment benefit patients, developing evidence to support reimbursement will become as 
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Introduction 
The health care system is in transition, exemplified by implementation of the Patient 
Protection and Affordable Care Act (ACA) in the United States [1]. A worldwide financial crisis 
has resulted in dwindling resources for medical services. The pressure to provide better care and 
treatment for people with Alzheimer’s disease (AD) and their families is particularly acute, as 
the number of people with dementing disease worldwide is expected to exceed 100 million by 
2050 [2]. In the United States the cost of Alzheimer care is higher than many other nations, yet 
the quality of dementia care is still poor, fragmented, and inadequately reimbursed [3].  
Randomized controlled trials (RCTs) have long been considered the “gold standard” for 
clinical research in humans [4] and the path that pharmaceutical companies follow in order to 
gain approval for new drugs from regulatory agencies. These trials are traditionally randomized, 
placebo-controlled and use highly selected patient populations to most convincingly demonstrate 
an effect on disease. Diagnostics are evaluated on their basis to reliably and selectively detect 
disease. Once approved, 3
rd
 party payers, government health plans and private insurance 
companies, must decide whether or not to reimburse the use of drugs and diagnostics.  Although 
without 3
rd
 party reimbursement individuals can have access by paying the full cost out-of-
pocket, drugs and diagnostics may be out of financial reach for many and availability may be 
severely restricted if pharmacies and providers decide to not offer them because of low demand. 
In recent years, 3rd party payers increasingly have been unwilling to automatically reimburse 
drugs and diagnostics based upon regulatory approval. Cognizant of both the escalating costs of 
new drugs and the desire to limit health care expenditures, they have decided to deny coverage 
despite evidence of significant benefits demonstrated in randomized clinical trials. The issue, 
according to payers, is that RCTs do not necessarily aim to or incorporate measures that 
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costs. Responding to those concerns, agencies have been established in the United Kingdom, 
Canada, and Australia to consider both comparative effectiveness and cost effectiveness in 
determining which treatments will be covered [5].  
While no disease-modifying drugs for AD or other dementias have reached clinical 
practice, three diagnostics for amyloid imaging have received regulatory approval [6-8] and there 
are nearly 100 medicines and diagnostics currently in development [9]. In anticipation of a new 
disease modifying and possibly expensive treatments for AD becoming available, the 
Alzheimer's Association’s Research Roundtable, a consortium of scientists from the 
pharmaceutical, biotechnology, imaging, and cognitive testing industries, met in Washington, 




, 2013, with insurers, health economists, regulatory and academic 
scientists, and policy experts to develop strategies that best address the concerns of payers while 
ensuring continued progress in drug development. 
 
1. Cost effectiveness, value, and payer perceptions 
The concept of value has moved to the forefront of healthcare decision making as per 
capita spending on health care is reaching unsustainable levels in the United States and many 
other countries without a corresponding improvement in health outcomes [10, 11]. Indeed, the 
ACA mentions value 214 times.  Payers looking for evidence of clinical effectiveness and value 
in real world settings often are not satisfied with the results from RCTs. RCTs developed for 
regulatory approval typically demonstrate effectiveness only using relatively small, 
homogeneous and unrepresentative clinic populations. Patients with co-morbid illnesses are 
generally excluded and it is uncertain results can be replicated outside the rigorous research 
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although these data are typically not available from clinical trials [12]. For example, payers think 
of benefits in terms of functional outcomes, while RCTs involving dementing disease typically 
emphasize and report on cognitive measures. Observational studies are useful for collecting real 
world data, although outcomes collected often differ across studies and fail to have adequate 
controls [13].   
The concept of “value” in health care can have many different meanings depending upon 
the perspective of those involved.  Patients, physicians, health care systems, companies, 
researchers, regulators, and both public and private payers apply different metrics of  “value”. 
For example, the “innovativeness” of a diagnostic test may be of high commercial value, but of 
little value to patients, doctors, or payers. Likewise, the benefit of an accurate and confident 
diagnosis may be of high value to patients and physicians, but difficult to measure and 
demonstrate to payers.  
A recent example emerged from the recent regulatory approvals of Amyvid, Vizamyl and 
Neuraceq positron emission tomography (PET) ligands that allow the in vivo imaging of amyloid 
in the human brain.  The effort to get payers to reimburse the clinical use of these imaging agents 
sparked the need to evaluate the utility of diagnostics for dementing diseases. The Institute for 
Clinical and Economic Review (ICER) at the Massachusetts General Hospital’s Institute for 
Technology Assessment convened a Policy Development Group (PDG) composed of experts 
from academia, health care providers, non-profit organizations, and the insurance and 
pharmaceutical industries to evaluate the available evidence to help guide decision making about 
insurance coverage for these tests [14]. They applied an evidence hierarchy developed in the 
early 1990s [15] to analyze the current literature. This analysis found that of 15 PET amyloid 
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assessed diagnostic impression. Importantly, none established analytic validity by capturing 
action based upon diagnosis, patient outcomes (e.g., cognitive/function decline), societal 
outcomes (e.g., cost-effectiveness), or technical efficacy. Thus, ICER concluded that these 
studies, although in compliance with FDA guidelines, failed to provide persuasive evidence that 
insurers could use to demonstrate improved outcomes. Improved patient outcomes become a 
critical part of the discussion for payers, particularly when current treatments have limited 
benefits, physicians don’t apply consistent diagnostic and treatment algorithms, and interventions 
may expose patients to unnecessary risks and costs. Without dramatic short-term treatment 
benefits, improved patient outcomes from use of diagnostic tests will be difficult to demonstrate, 
particularly improvement in daily function. 
Roundtable discussion found that payers currently use the same methods for judging the 
value of diagnostics and drug treatments, despite their different purpose. For payers in the United 
States, there is no dominant structured process for rating benefits and costs in a formal decision-
making process as exists in other countries. Instead, each individual health plan and public payer 
has its own system for review. In terms of diagnostics, payers are more likely to find testing 
compelling when it influences the use of expensive or high risk treatments or when testing is 
limited to a narrow population shown conclusively to benefit. Accountable care organizations 
will play an increasingly important role in decision making about the value of tests and 
treatments as they are embedded in a system of care. 
 
3.0 Improving value: prevention and care management 
In the United States, implementation of the ACA and the National Plan to Address 
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the value. Secondary prevention (i.e. preventing symptoms after Alzheimer pathology is present) 
and tertiary prevention (i.e. preventing dementia when symptoms are already present) currently 
are being pursued and are considered potentially attainable goals of treatment [17-23]. Thus, 
payers are particularly interested in evidence regarding clinical effectiveness and value in 
treating mild cognitive impairment and better understanding the outcomes of those with 
biomarker evidence of amyloid pathology.  
Simulation models of different patient scenarios enable payers, researchers, and policy 
makers to estimate the costs and benefits of both diagnostic and treatment strategies for AD [24]  
For example, Cohen et al. modeled a hypothetical disease modifying treatment using a modestly 
priced biologic agent, with treatment effectiveness assumptions based on early trial results [25]. 
Assuming that the treatment had no impact on life expectancy, and omitting diagnostic costs, the 
model demonstrated greater cost effectiveness in younger patients and in patients with MCI 
compared to AD. When a diagnostic test that selected patients likely to benefit from the 
treatment was added to the model, costs increased as did the benefits, especially in younger 
patients at earlier stages of disease.  
Targeted early intervention is not only more cost effective but has other benefits in terms 
of better outcomes from secondary prevention measures. Preventing complications of the disease 
and managing co-morbidities, accomplished through better care management of individuals with 
multiple chronic conditions, also holds promise for improving the value of care [26]. Indeed, 
several successful care management programs proved successful in delivering high-quality 
dementia care to patients and caregivers through the use of well-defined protocols and tools and 
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Care management is an issue not only for health care providers but for insurers as well. 
Insurers may not identify AD as a singular condition, but as a complex, progressive chronic 
illness that is best managed through a carefully constructed progressive specialized program. For 
example, diabetes is typically managed in this way, with interventions identified at each stage 
that can prevent progression to the next stage. Whether a similar map can be created for AD is 
speculative at present, requiring markers at various levels of disease severity that can 
demonstrate the effectiveness of treatment.  
Payers in different countries and settings view AD through different lenses. For example, 
recognition and awareness about the importance of AD is high in the United Kingdom and 
elsewhere in Europe (but less so in Asia), with national policies placing a high priority on 
determining the cause of dementia and providing treatment and comprehensive care. As a result 
of those policies, the willingness to pay varies across countries.  In China, for example, AD 
drugs are not included in the National Reimbursement Drug List (NRDL) or the Essential Drug 
List (EDL), which outline reimbursement rates in different settings.  Reimbursement for 
diagnostics also varies across countries.  
Awareness is increasing in the United States, where the Medicare annual wellness visit 
now includes a cognitive assessment. Yet while this suggests that Medicare recognizes the 
importance of early identification of cognitive decline, reimbursement for amyloid PET imaging, 
a newer technology that might also aid in early identification, is not covered by most private 
insurers or by Medicare, except under Coverage with Evidence Development or CED [30]. 
Medicare has a prescription drug benefit, but lacks a comprehensive plan to ensure better AD 
care, with coverage benefits varying according to the care setting. Demonstration projects funded 
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models for improving care delivery for patient. One of these, the Aging Brain Care (ABC) model 
at Indiana University [31], which was developed to provide improved and cost-effective care to 
people with dementia and their families, has been implemented in Indiana’s Wishard Health 
Services system, with anticipated cost savings estimated at 30%.  
 
4.0 Filling the evidence gaps 
Despite the fact that there are some 19,000 RCTs published every year, along with tens of 
thousands of other clinical studies, systematic reviews routinely conclude that the quality of 
evidence is poor. For example, The American College of Physicians (ACP and American 
Academy of Family Physicians (AAFP) reviewed available evidence on drug treatments for 
dementia in 2008, concluding that there was weak evidence to support existing clinical 
recommendations, including no convincing comparative studies, the use of outcome measures 
not routinely used in clinical practice, and trials with insufficient follow-up [32].  At the 
regulatory level, a few agencies provide forums for dialogue, advice, and guidance regarding the 
data needed for trials, but at the payer level, public and private payers make varying independent 
decisions. Moreover, payers have limited capacity within their organizations to provide advice or 
guidance to regulators or researchers, nor do they have the expertise or mechanism to coordinate 
communication about evidence. 
Researchers and 3
rd
 party payers have developed strategies to address gaps between the 
evidence obtained in typical RCTs and evidence needed to establish real world effectiveness. 
Comparative effectiveness research, a central feature of the ACA, is designed to assess 
outcomes, quality of life, and survival. Importantly, it also provides better evidence to inform 
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in choosing treatment alternatives. Yet comparative effectiveness trials also have disadvantages, 
making studies larger, more complicated, and more expensive.  
The Center for Medical Technology Policy (CMTP), an independent non-profit aimed at 
making health care more effective and affordable, established the Green Park Collaborative to 
develop condition-specific recommendations regarding evidence needed to support decision-
making on coverage and payment issues. In April, 2013, the Collaborative released an evidence 
guidance document on the design of clinical studies of AD therapies [33]. Their 
recommendations addressed the representativeness of enrolled subjects, including inclusion and 
exclusion criteria; interventions and comparators; primary and secondary outcome assessments; 
the need for standardization; and the need to include a measure of effects on care partners.  
The scientific evidence payers need to make reimbursement decisions may be similar to 
that needed by academics and regulators developing guidelines, but how that evidence is 
evaluated and the importance of various aspects of the evidence varies significantly. For 
example, in developing guidelines for market approval, the strength of the evidence and 
magnitude of benefit may be of primary importance, while payers want to determine if the 
treatment or diagnostic is medically necessary and whether it improves health outcomes.   
The desire by payers for better evidence of functional improvement is complicated in the 
early disease by the lack of functional deficits in preclinical AD. The FDA suggested in its recent 
draft guidance [34] that for clinical trials, cognitive tests linked to biomarker outcomes may 
support a claim of disease modification. How the payer community will deal with preclinical AD 
has yet to be determined, and is complicated by data showing that a substantial number of 
individuals diagnosed with MCI revert back to normal [35, 36]. One factor contributing to these 
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including both informant- and patient-reported measures [37]. How the diagnosis is reached will 
also play a role, with the specificity of subjective memory complaint diminishing as the 
diagnostic setting moves from specialty to primary to community care.  
 
5.0 The regulatory perspective on payer concerns 
The FDA issued a draft guidance in February 2013 about developing drugs for treatment 
of early stage AD [34, 38]. The draft guidance provides a framework for how drugs might be 
studied in early AD trials. While drugs for dementia are required to show benefits on both 
cognition and global function with separate outcome measures, the new draft guidance is specific 
to drugs for patients early in the disease process and symptom manifestation where few 
functional deficits may exist and sensitive functional scales are not available. The draft guidance 
thus outlines two possible ways that drugs might be approved: 1) for patients with early 
Alzheimer's disease dementia, a single primary outcome measure that combines cognition and 
function, such as the CDR Sum of Boxes (CDR-SB) [39] could be used; 2) for patients in the 
earliest stages of the disease with the most to gain from treatment but where clinical benefits are 
difficult to demonstrate, the guidance points to the accelerated approval mechanisms, which 
already exists in the Code of Federal Regulations (21 CFR 314.510).  
The accelerated approval pathway allows drugs that address an unmet medical need to be 
approved based on a surrogate endpoint or an effect on an intermediate clinical endpoint such as 
a sensitive cognitive measure, with further post-marketing evaluation required to demonstrate a 
clinically meaningful effect.  Utilization of this pathway requires both accurate identification of 
patients and identification of a biomarker or cognitive measure that captures early changes, two 
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The FDA also regulates imaging devices used in connection with AD, and while similar 
principles guide the decision-making for drugs and diagnostics -- for example, risk-benefit 
considerations -- imaging products are not expected or required to demonstrate therapeutic 
benefits. For radiopharmaceuticals, approval is contingent on clarity of proposed use, 
pharmacologic activity, potential toxicity, estimated absorbed radiation dose, and demonstration 
that the product provides useful, accurate, and reliable clinical information.  
While the FDA does not consider value as defined by payers in its decisions, and does 
not require elements to be incorporated into trials that would demonstrate value, FDA 
representatives have expressed willingness to engage in dialogue to address the concerns of 
payers. They pointed out, however, that requiring trials to enroll more heterogeneous populations 
with more co-morbidities and concomitant medications could have adverse consequences on the 
drug development process by introducing excessive variability in the target population and 
blurring evidence of possible treatment effects, making studies considerably more complicated 
and expensive. However, introducing endpoints, such as time to hospitalization, and trying to 
correlate those endpoints with changes on cognitive or functional measures might be possible to 
incorporate and speak to the question of value.  
 
6.0 Conclusions 
While the contrast between concerns of drug developers and payers is evident, the need for 
dialogue is clear. Pharmaceutical companies are beginning to shift their focus to consider not 
only whether a drug is going to work but also whether or not a reimbursement pathway is 
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health outcomes (See Text Box). They are asking for more information, not just whether a drug 












There is an urgent need to change the way conventional clinical research is conducted, 
which focuses on FDA approval rather than developing and disseminating a drug that is accepted 
by the health care system. Developing a new research model will necessitate establishing large 
registries, longitudinal databases, and big data approaches to mine and analyze large amounts of 
data.  An additional emerging need identified in the United States is to establish a peer-review 
process or oversight body for reimbursement decisions, similar to that which exists in the United 
Kingdom, Australia, and Canada. Such an agency might develop a standard for evidence 
requirements and reimbursement, which would enable trials designed to meet those standards. 
Worldwide changes in the delivery of health care have shifted the emphasis toward 
improving patient outcomes and preventing disease, despite the fact that programs which provide 
Standards and evidentiary requirements for payer 
decision-making 
 
 Better measures that capture information about real 
world functional impairments, including social 
functioning.  
 Better means of targeted interventions with greater 
specificity.  
 Evidence collected in real-world settings including 
primary care practices. 
 Evidence that is sufficiently robust to compare to other 
interventions. 
 Evidence that efficacy will translate into effectiveness. 
 Evidence that clinical effectiveness will translate into 
tangible patient benefits. 
 Evidence establishing the relationship between short-
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this kind of patient-centered care face barriers in terms of reimbursement. The challenge is multi-
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